Cooley advised AN2 Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. AN2 Therapeutics, Inc. announced its upsized initial public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised IDEAYA Biosciences, while Davis Polk advised the underwriters in the offering. IDEAYA Biosciences, Inc. executed its public offering of 5,333,333 shares of common...
You must be a Standard 1 Year member to access this content.
Cooley advised RAPT Therapeutics, while Davis Polk advised the joint book-running managers in the offering. with a $143.7 million SEC-registered follow-on offering of 4,356,060 shares of...
You must be a Standard 1 Year member to access this content.
Davis Polk advised the joint book-running managers and representatives of the several underwriters in the offering. Nurix Therapeutics, Inc. completed its follow-on offering of 5,175,000 shares...
You must be a Standard 1 Year member to access this content.
